MCL1 and neuroblastoma: In the CDDP-resistant cells, the synergy was maintained for those combinations including the MCL1 inhibitor S63845, whereas the combined inhibition of BCL2 and BCL-XL was less effective and even antagonistic in the CDDP SH-SY5Y cells, thus underscoring the importance of MCL1 as a therapeutic target in chemoresistant neuroblastoma.